Aaronson, Scott, 136
Ablation studies, 2
Acoustic changes, 34
Adolescent populations, TMS for, 27
Adverse effects. See also Safety
acoustic trauma, 34
cognitive, 35
loss of consciousness, 107–108
migraine, 34
pain, 34
syncope, 45
tinnitus, 38
Aldini, Giovanni, 1
Alzheimer’s disease, 109, 126–127
Antidepressant therapies
advantages and disadvantages of, 55–56
as standard treatment, viii
Antidepressant treatment history form (ATHF), 54
Aphasia, 127
Assessment of patients, 52–53. See also Patient selection
Auditory hallucinations, treatment of, 38, 125, 147
Autonomic adverse effects, 36–37
Avery, D. H., 23
Bae, E., 63
Barker, Anthony, vii, 3, 8, 17, 98
Beck Depression Inventory-II (BDI-II), 89
Beer, Berthold, 3
Berger, Hans, 103
Bienenstock-Cooper-Munro model of plasticity, 38
Bilateral rTMS, 120
Bipolar disorder, 26, 35, 61, 122–123
Blumberger, Daniel M., 98
Borderline personality disorder, 53
Brain stem regions, viii
Burt, T., 22
Buzsaki, G., 100
Calgary Depression Scale for Schizophrenia, 124
Capacitor, Leyden jar as, 1
Carcot, Jean-Martin, 2
Center for Epidemiologic Studies Depression Scale (CESD), 90
Centers for Medicare & Medicaid Services, 60, 79
Children and adolescents, TMS for, 34, 37
Children’s Depression Rating Scale-Revised (CDRS-R), 27, 91
Cingulate gyrus, viii
Clinical efficacy of TMS in depression, 17–31
combination trial, 21
electroconvulsive therapy versus, 23–24
large-scale RCT results, 18–20
low frequency right sided rTMS, 119–120
in Parkinson’s disease, 128
post stroke depression, 61, 139
priming approach, 121
special populations, 27
TMS rationale for, viii–ix, 145–146
treatment-resistant depression, 4, 18
Clinical trial design, limitations in, 157–159
Cochlear implants, 40
Cochrane reviews, 125
Cognitive behavioral therapy, 28
Coil configuration
“deep” TMS device, 70
estimation of TMS intensity and effect, 13–15
future directions for, 164
H-shaped, 42
patient selection and, 62
Combination TMS, efficacy for depression, 37–40
Connectivity-guided coil placement, 164
Contraindications and precautions, 45–46
Cortical pathways, stimulation of, vii
Cortical silent period (CSP), 99–100
Cristancho, Mario A., 17
Current Procedural Terminology (CPT) codes, 79
d’Arsonval, Jacques-Arsène, 3
Daskalakis, Zafiris J., 98, 100, 106
Deep brain stimulation (DBS), 39–40, 143–145
“Deep” TMS device, 70
Depression. See Clinical efficacy of TMS in depression
Descartes, René, 1
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), 87
Diffusion MRI, 33
Discontinuation rates, 23
Dorsolateral prefrontal cortex (DLPFC)
depression and abnormal activity in, viii–ix
locating, 11
pain perception by, 126
Efficacy. See Clinical efficacy of TMS in depression
Elderly populations, TMS for, 83
Electroconvulsive therapy (ECT)
in depression treatment, viii
side effects and tolerability, 137–138
speed of response, 138
TMS versus, 23–24, 58–60, 119, 138
Electrodynamics, 2
Electroencephalography (EEG)
brain rhythms measured by, 105–106
paired-pulse TMS combined with, 106–107
single-pulse TMS combined with, 106
sleep affected by TMS with, 107
TMS combined with, 4, 103–105, 108–109
Electromagnetism, laws of, 8
Electromyography (EMG), 41, 44, 98
Electrophysiology, 17
Epstein, Charles M., 8
Excitatory TMS paradigms, 100–101
Ferrarelli, F., 107
Ferreri, F., 107
Ferrier, David, 2
Fibromyalgia, 126
Fiducials (skull landmarks), 11
Figiel, G. S., 27
Food and Drug Administration (FDA). See U.S. Food and Drug Administration (FDA)
Fox, M. D., 12
Frantseva, M., 108
Freud, Sigmund, 3
Fritz, Gustav, 2
Functional magnetic resonance imaging (fMRI), 4
Functions of the Brain (Ferrier), 2
Galen of Pergamum, 1
Galvani, Luigi, 1
Gamma-aminobutyric acid (GABA) inhibitory neurotransmission, 99–100
Geriatric depression scale (GDS), 91–92
Hallucinations, 38, 47, 125, 147
Hamilton Rating Scale for Depression (HRSD), 18, 23, 84, 87–88
Harvey, William, 1
Hearing loss, 34. See also Auditory hallucinations
Hebbian plasticity, 4
Hitzig, Eduard, 2
Holtzheimer, Paul E., vii, 21, 27, 136
Hoppenbrouwers, S., 108
ICF paired-pulse paradigm, 101, 107
Ilmoniemi, R., 104
Implantable pulse generator (IPG), 40
Infrared neuronavigation, 11
Inhibitory TMS paradigms, 99–100
Insular cortex, viii
Insurance reimbursement, 60, 78–79
Intensity, estimation of, 13–15
Interhemispheric signal propagation, 4
Internal pulse generator (IPG), 40
International Federation of Clinical Neurophysiology (IFCN), 32
International Society for ECT and Neurostimulation (ISEN), 71
Inventory of Depressive Symptomatology (IDS) and Quick IDS (QIDS) measurement, 89–90
Jackson, Hughlings, 2
Janicak, P. G., 22
Jorge, R., 154
Kaptsan, A., 61
Keel, J. C., 72
Kicic, D., 104
Kimbrell, T., 37
Kozel, F. A., 22
Landy, Michelle, 17
Lefaucheur, Jean-Pascal, 32
Levels of evidence, 21
Leyden jar (as capacitor), 1
Lisanby, Sarah H., 152
Localisation of Cerebral Disease, The (Ferrier), 2
Long-interval cortical inhibition (LICI), 99–100, 106–108
Long-term potentiation (LTP), 4
Low frequency right sided rTMS, 119–120
Magnetic resonance imaging (MRI), 11, 20, 44
Magnetic seizure therapy (MST), 138–139
Magstim, Inc., 70
MagVenture, Inc., 70
Maintenance TMS, 153
Maixner, Daniel F., 69
Major depressive disorder (MDD). See Clinical efficacy of TMS in depression
Mantovani, A., 22
Manufacturer and User Facility Device Experience (MAUDE) database, FDA, 155–156
Massimini, M., 107
Matsumiya, Y., 33
McCall, W. Vaughn, 52
McClintock, Shawn M., 82
McDonald, William M., vii
McNamara, B., 21
Beck Depression Inventory-II, 89
Center for Epidemiologic Studies depression scale (CESD), 90
Children’s Depression Rating Scale-Revised (CDRS-R), 91
Geriatric Depression Scale (GDS), 91–92
Inventory of Depressive Symptomatology (IDS) and Quick IDS measurement, 89–90
Montgomery-Asberg Depression Rating Scale (MADRS), 88–89
neuropsychologic function screening, 92–94
Patient Health Questionnaire (PHQ-9), 90–91
psychometric considerations, 83
Medial prefrontal cortex, viii
Medial temporal lobe regions, viii
Mesmer, Franz, 1
Metaplasticity concept, 38
Midbrain, viii
Mindfulness therapy, 28
Mini Mental State Examination (MMSE/MMSE-2) screening, 92–93
Montgomery-Asberg Depression Rating Scale (MADRS), 18–19, 84, 88–89
Montreal Cognitive Assessment (MoCA) measure of cognitive function, 93–94
Mood-regulation circuit, of brain, ix
Motor cortex stimulation, 101–103, 125–126
Motor-evoked potential (MEP), 41–42, 98
Motor-evoked potential (MEP) amplitude, 100–101
Motor threshold, 13–14. See also Resting motor threshold (RMT)
Multimodal paradigms for TMS, 166
National Institutes of Health (NIH). See U.S. National Institutes of Health (NIH)
Negative symptoms, in schizophrenia, 124
Neosync, Inc., 70
Neurological disorders. See Psychiatric and neurological disorders, TMS for
Neuronetics, Inc., 70
Neurophysiological measure of TMS, 98–116
cortical excitability, 101–103
electroencephalography (EEG)
brain rhythms measured by, 105–106
paired-pulse TMS combined with, 106–107
single-pulse TMS combined with, 106
sleep affected by TMS measured by, 107
TMS combined with, 103–105, 108–109
excitatory TMS paradigms, 100–101
future directions, 110
inhibitory TMS paradigms, 99–100
loss of consciousness studies, 107–108
Neuropsychiatric disorders. See Psychiatric and neurological disorders
Neuropsychological screening, 92–94
Neurostar rTMS device (Neuronetics), 18–19, 47
Neurostimlation intervention development, 136–151
deep brain stimulation, 143–145
electroconvulsive therapy (ECT), 136–138
magnetic seizure therapy (MST), 138–139
repetitive TMS (rTMS), 145–147
transcranial direct current stimulation (tDCS), 139–140
vagus nerve stimulation (VNS) implantable device, 140–143
Neurostimulation practitioners, 60
Noninvasive brain stimulation, 2
Obsessive-compulsive disorder (OCD), 123, 143
Optimization of TMS trial (OPT-TMS), 20
Orbitofrontal cortex, viii
Outcome predicting and influencing, 60–64
Parietal cortex, viii
Patient Health Questionnaire (PHQ-9), 90–91
evaluation and monitoring, 71–72
limitations in methods of, 154
Patterned stimulation, 121
Pharmacotherapy, TMS versus, 22–23
Pollacsek, Adrian, 3
Post-stroke depression, 61, 139
Posttraumatic stress disorder (PTSD), 123
Potter, Guy, 82
Psychiatric and neurological disorders, TMS for, 117–135
Alzheimer’s disease and dementia, 109, 126–127
aphasia, 127
bipolar disorder, 26, 35–36, 61, 122–123
borderline personality disorder, 53
obsessive compulsive disorder, 123
Parkinson disease, 128
post-stroke depression, 61, 128, 139
posttraumatic stress disorder treatment, 123
schizophrenia and psychosis, 124–125
stroke-related neurological impairment, 127–128
Psychometric considerations, in measurement-based care, 83, 87
Quick Inventory of Depressive Symptomatology (QIDS) and IDS measurement, 89–90
Radhu, Natasha, 98
Reimbursement, insurance, 60, 78–79
Relapse, in depression, viii
Repeatable battery for the assessment of neuropsychological status (RBANS), 94
Repetitive TMS (rTMS). See also Psychiatric and neurological disorders, TMS for
cortical excitability from, vii
developmental stages of, 17
in neurostimulation intervention development, 145–147
single-pulse TMS enhanced by, 3
Research methodology, limitations in, 157–159
Resting motor threshold (RMT), 13–14, 41, 99–101
Rosenquist, Peter B., 52
Rosonova, M., 107
Safety, 32–51. See also Seizures
children and adolescents, 34, 37
cochlear implants, 40
concurrent diseases and, 37–40
contraindications and precautions, 45–46
Manufacturer and User Facility Device Experience (MAUDE) database, 155–156
neuropsychological screening, 92–94
stimulation parameters and, 41–44
TMS limitations based on, 155–157
Transcranial magnetic stimulation Adult Safety Screen (TASS), 63
Schizophrenia, 38, 47, 124–125
Seizures
management of, 45
as TMS acute adverse event, 32–33
Self-report inventories, 89
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial, 23, 58–59
Sham/masking, in clinical trials, viii, 157–158
Shelly, Mary, 1
Short-interval cortical inhibition (SICI), 100, 107
Short latency afferent inhibition, 4
Single-pulse TMS, 106
Speed of response, 153
Stroke-related neurological impairment, treatment of, 127–128
Swammerdam, Jan, 1
“Synchronized” TMS, 70
Syncope, 45
Taylor, Joseph J., 1
Thalamus, viii
Theta burst stimulation (TBS), 4, 14, 43, 121
Tinnitus, 38
insurance reimbursement, 78–79
patients
selection and monitoring, 71–72
personnel and training, 71
standard operating procedures and policies, 75–78
TMS devices, 70
TMS, efficacy of. See Clinical efficacy of TMS in depression
TMS, future directions for, 162–166
intensity and effect estimation, 13–15
clinical trial design and research, 157–159
patient selection methods, 154
potency, speed of response, and maintenance, 153
Transcallosal inhibition (TCI), 100
Transcranial direct current stimulation (tDCS), 139–140
Transcranial magnetic stimulation adult safety screen (TASS), 63
Treatment-resistant depression (TRD), 4, 18
Turner, E. H., 22
U.S. Food and Drug Administration (FDA)
Manufacturer and User Facility Device Experience (MAUDE) database, 155–156
Neuronetics Neurostar rTMS device approved by, 47
rTMS device approved by, vii–viii, 3, 17
TMS devices approved by, 70
vagus nerve stimulation approved by, 141
U.S. National Institutes of Health (NIH), 14, 18, 20, 57
Vagus nerve stimulation (VNS)
developmental difficulties, 143
implantable devices for, 141
insurance coverage for, 60
overview, 141
side effects and tolerability, 142
for treatment-resistant patients, 54, 57
U.S. Food and Drug Administration (FDA) approval of, 141
Validity of measurement instruments, 83, 87
Visual hallucinations, 38
Voineskos, A., 109
Volta, Alessandro, 1
Wall, C. A., 27
Wang, X., 100
Zanjani, Anosha, 98
Ziemann, U., 100